Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers Get access Arrow Jul 10, 2025 | Lymphopenia
Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer Mar 27, 2025 | Ovarian Cancer
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Aug 5, 2024 | Non-Hodgkin Lymphoma
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques May 10, 2024 | HIV
Safety and virologic impact of haploidentical NK cells plus IL-2 or N-803 in HIV infection May 10, 2024 | HIV
